Ethanol (EH)

EHang Holdingsの空売り状況は、投資家がEHang Holdingsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

EHang Holdings (NASDAQ:EH) 株価情報, 空売り情報

EHang Holdings

EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.

EHang Holdings Ltd

Enhabit Inc

Encompass Health Corporation Common Stock

Encompass Health Corp

Eshallgo Inc

STAR ENTMT GROUP LTD ORD by Star Entertainment Group Limited

The Star Entertainment Group Ltd

Western Asset Global High Income Fund Inc Common Stock

Western Asset Global High Inc Fd Inc

EDINBURGH INVST TR by Edinburgh Investment Trust

Euroholdings Ltd

EUROHOLDINGS LTD ORD WHEN ISSUED

Even Herd Long Short ETF

goeasy Ltd

Ehouse Global Inc

EAGLE HOSPTLTY PPT/TR PFD by Eagle Hospitality Properties Trust Inc.

eHealth Inc

Ehave Inc

EHYDROGEN SOLUTIONS INC by Ehydrogen Solutions, Inc.

News

AREB

American Rebel Expands Into 62 Total Wine & More Locations

UBS analyst Brian Meredith maintains Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) with a Buy and lowers the price target from $606 to $591.

Price Target

Analyst Ratings

BRK/B

UBS Maintains Buy on Berkshire Hathaway, Lowers Price Target to $591

Riot Produces 514 Bitcoin in May 2025
CASTLE ROCK, Colo., June 3, 2025 /PRNewswire/ -- Riot Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) ("Riot" or "the Company"), a Bitcoin-driven industry leader in the development of large scale data centers for high performance compute and bitcoin mining applications, announces unaudited production and operations updates for May 2025.&nbsp;&nbsp;

RIOT

Riot Announces May 2025 Production And Operations Updates; Produces 514 Bitcoin In May 2025

Baird analyst Timothy Wojs maintains Toro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTC#NYSE">TTC</a>) with a Neutral and raises the price target from $84 to $85.

Baird Maintains Neutral on Toro, Raises Price Target to $85

Cantor Fitzgerald analyst Matthew Vanvliet initiates coverage on Agilysys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) with a Overweight rating and announces Price Target of $125.

Initiation

AGYS

Cantor Fitzgerald Initiates Coverage On Agilysys with Overweight Rating, Announces Price Target of $125

<ul>
<li>Keysight obtains regulatory clearance in the U.S. for its acquisition of Spirent Communications</li>
<li>Agreement to divest Spirent's high-speed ethernet, network security, and channel emulation business lines</li>
<li>Scheme expected to become effective during the third quarter of Keysight's fiscal 2025</li>
</ul>

Government

Regulations

KEYS

VIAV

Keysight Technologies And Spirent Communications Enter Into Consent Decree With US DOJ In Connection With Review Of Proposed Acquisition With Spirent

HSCS

HeartSciences Granted Foundational Patent For AI-Powered ECG Technology Advancing Heart Disease Detection

UBS analyst Brian Meredith maintains Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) with a Buy and lowers the price target from $909218 to $887099.

BRK/A

UBS Maintains Buy on Berkshire Hathaway, Lowers Price Target to $887099

PennyMac Mortgage Investment Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMT#NYSE">PMT</a>) (the "Company" or "PMT") today announced that it is commencing an underwritten public offering of senior notes due 2030 (the "Notes"). The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by PennyMac Corp. ("PMC"), an indirect wholly-owned subsidiary of the Company. The Company intends to use the net proceeds from the offering to fund its business and investment activities, which may include: the investment in subordinated bonds from its private-label securitization activities and other mortgage-related securities; the acquisition of mortgage servicing rights; funding the Company's correspondent lending business, including the purchase of Agency-eligible residential mortgage loans; repayment of other indebtedness, which may include the repurchase or repayment of a portion of PMC's 5.50% exchangeable senior notes due 2026 or secured financing; and for other general business purposes. The interest rate and other terms of the Notes will be determined at the time of pricing the offering.

Offerings

PennyMac Mortgage Announces It Is Commencing An Underwritten Public Offering Of Senior Notes Due 2030

Cantor Fitzgerald analyst Matthew Vanvliet initiates coverage on Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) with a Overweight rating and announces Price Target of $110.

QTWO

Cantor Fitzgerald Initiates Coverage On Q2 Holdings with Overweight Rating, Announces Price Target of $110

Applied Digital Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) didn't just catch a tailwind from AI hype &#8211; it may have secured a hurricane. Monday's <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45721501/applied-digital-stock-surges-on-ai-data-center-deal-with-coreweave-what-you-need-to-know">nearly 50% explosion</a> in share price wasn't a fluke; it was a visceral market reaction to a $7 billion, 15-year lease deal with AI cloud heavyweight Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)-backed CoreWeave Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>).
This once-sleepy infrastructure play suddenly has the potential to be Wall Street's latest AI adjacency darling.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0603"><img loading="lazy" decoding="async" width="631" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074421/Screenshot-2025-06-03-at-3.46.51-PM.png" alt="" class="wp-image-936507" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074421/Screenshot-2025-06-03-at-3.46.51-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074421/Screenshot-2025-06-03-at-3.46.51-PM-300x231.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0603">Chart created using Benzinga Pro</a>
But here's where things get interesting: with 30% of Applied Digital's float shorted &#8211; over 62 million shares, according to Benzinga Pro data &#8211; and the stock breaking through every major moving average like a hot knife in butter, the setup for a short squeeze is no longer just theoretical. It's a live wire.
Read Also: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45647027/is-nvidia-backed-coreweaves-195-may-rally-a-massive-short-squeeze-in-the-making">Is Nvidia-Backed CoreWeave&#8217;s 195% May Rally A Massive Short Squeeze In The Making?</a><a href="https://twitter.com/surbhijain123" target="_blank" rel="noreferrer noopener"></a><a href="https://twitter.com/surbhijain123" target="_blank" rel="noreferrer noopener"></a>
The fundamentals? The company's pivot into high-performance computing is finally gaining traction. This CoreWeave deal alone could generate nearly half a billion dollars <a href="https://www.cnbc.com/2025/06/02/applied-digital-coreweave-ai.html">annually</a>, anchoring Applied Digital's move away from crypto-dependency and deeper into AI infrastructure &#8211; a sector that commands far richer valuations. 
Add in technicals that are flashing bullish across the board. The MACD (moving average convergence/divergence) indicator rising, the SMAs (simple moving averages) making bullish crossovers and the RSI (relative strength index) at 77.69 &#8211; the momentum doesn't look like it's cooling anytime soon.
Still, there's tension beneath the surface. Bears worry about execution risks and delayed revenue recognition &#8211; and they're not wrong to watch for potential bottlenecks in GPU delivery and facility buildouts. But that's tomorrow's concern. 
Today, Applied Digital stock just woke up with a catalyst strong enough to reprice the whole narrative.
The next big move? Watch the short interest and volume closely. If momentum sustains and the stock stays above $10, the chase could force skeptics to rethink or capitulate.
In a market where AI infrastructure is the new gold rush, Applied Digital may have just staked its claim. Whether it becomes a CoreWeave-dependent one-hit wonder or a hyperscaler-backed breakout name is still unfolding &#8211; but for now, Applied Digital has the attention, the deal and the tape on its side.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45727395/tom-lee-predicts-bitcoin-to-hit-250000-by-end-of-2025-3m-long-term">Tom Lee Predicts Bitcoin To Hit $250,000 By End Of 2025, $3M Long Term</a></li>
</ul>
Photo: Shutterstock

Tech

APLD

CRWV

NVDA

Applied Digital's Stunning 48% Rally May Put Shorts On The Run

CXDO

Crexendo Announces Expanded Partnership With UDT To Power Voice Solution With NetSapiens Platform

Buybacks

BON Natural Life Announces Share Repurchase Program Of Up To $1M

Cantor Fitzgerald analyst Matthew Vanvliet initiates coverage on Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Overweight rating and announces Price Target of $325.

Cantor Fitzgerald Initiates Coverage On Salesforce with Overweight Rating, Announces Price Target of $325

<a href="https://www.reuters.com/business/autos-transportation/teslas-model-3-model-y-make-list-chinas-campaign-boost-rural-ev-sales-2025-06-03/" title="https://www.reuters.com/business/autos-transportation/teslas-model-3-model-y-make-list-chinas-campaign-boost-rural-ev-sales-2025-06-03/">https://www.reuters.com/business/autos-transportation/teslas-model-3-model-y-make-list-chinas-campaign-boost-rural-ev-sales-2025-06-03/</a>

TSLA

Reuters Earlier Reported 'Tesla's Model 3, Model Y Make List Of China's Campaign To Boost Rural EV sales'

UBS analyst Timothy Chiodo maintains Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Buy and raises the price target from $660 to $670.

UBS Maintains Buy on Mastercard, Raises Price Target to $670

In the preceding three months, 6 analysts have released ratings for Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $56.17, a high estimate of $70.00, and a low estimate of $44.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.46%. 
<img src="https://www.benzinga.com/files/images/story/2025/1748955674_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Kymera Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Joseph</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Alex Thompson</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$70.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$52.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Kymera Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Kymera Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Kymera Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Kymera Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KYMR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Kymera Therapeutics analyst ratings.</a>
<h2>Discovering Kymera Therapeutics: A Closer Look</h2>
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
<h3>Financial Milestones: Kymera Therapeutics's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Kymera Therapeutics's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 114.83%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Kymera Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -296.75% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Kymera Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -8.09%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Kymera Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -6.92%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.11, Kymera Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KYMR

What 6 Analyst Ratings Have To Say About Kymera Therapeutics

In the preceding three months, 8 analysts have released ratings for Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $33.12, a high estimate of $40.00, and a low estimate of $21.00. Experiencing a 2.59% decline, the current average is now lower than the previous average price target of $34.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1748955666_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Xometry is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cory Carpenter</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Bruno Montanari</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$36.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Troy Jensen</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Underweight</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$32.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Cory Carpenter</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Xometry. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Xometry compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Xometry's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Xometry's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/XMTR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Xometry analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Xometry</h2>
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
<h3>Unraveling the Financial Story of Xometry</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Xometry's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 23.05% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -9.99%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Xometry's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -4.83%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -2.2%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Xometry's debt-to-equity ratio is below the industry average at 0.95, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

XMTR

Expert Outlook: Xometry Through The Eyes Of 8 Analysts

In the latest quarter, 9 analysts provided ratings for Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Fortive, presenting an average target of $79.89, a high estimate of $87.00, and a low estimate of $69.00. A decline of 4.39% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1748955656_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Fortive is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Richard Eastman</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$72.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$69.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$81.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Fortive. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Fortive compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Fortive's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FTV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Fortive analyst ratings.</a>
<h2>Unveiling the Story Behind Fortive</h2>
Fortive is a diversified industrial technology firm with a broad portfolio of mission-critical products and services that include field solutions, product realization, health, and sensing technologies. The company serves a wide range of end markets, including manufacturing, utilities, medical, and electronics. Fortive generated roughly $6.2 billion in revenue in 2024.
<h3>Fortive's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Challenges: Fortive's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -3.3%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Fortive's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 11.66%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Fortive's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.68%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Fortive's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.01%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Fortive's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.38.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Fortive's Future

4 analysts have expressed a variety of opinions on ASGN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $60.0, a high estimate of $75.00, and a low estimate of $54.00. A decline of 34.78% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1748955648_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of ASGN by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$56.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$55.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Kevin Mcveigh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$54.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ASGN. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ASGN compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for ASGN's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into ASGN's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ASGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ASGN analyst ratings.</a>
<h2>Unveiling the Story Behind ASGN</h2>
ASGN Inc is a provider of information technology (IT) services and professional solutions, including technology, creative, and digital, across the commercial and government sectors. It operates through two segments, Commercial and Federal Government. The Commercial Segment, which generates the majority of the revenue, provides consulting, creative digital marketing, and permanent placement services to Fortune 1000 clients and mid-market companies. The Federal Government Segment provides mission-critical solutions to the Department of Defense, intelligence agencies, and civilian agencies.
<h3>ASGN: Delving into Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3M period, ASGN faced challenges, resulting in a decline of approximately -7.69% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: ASGN's net margin excels beyond industry benchmarks, reaching 2.16%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): ASGN's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.17%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.59%, the company showcases effective utilization of assets.
Debt Management: ASGN's debt-to-equity ratio is below the industry average. With a ratio of 0.75, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASGN

Demystifying ASGN: Insights From 4 Analyst Reviews

Press Releases

Drone Surveying Market One of The Fastest Growing Segments of the Drone Industry as Revenue Opportunity Climbs

EHang States No Impact on Operations from Recent U.S.–China Tariff Actions

Versatility Of Commercial Drones Performing Growing Number of Tasks is Driving Rapidly Increasing Adoption Rate

EHang Files Annual Report on Form 20-F for Fiscal Year 2024

Global Drone Market Projected to Reach $57.8 Billion By 2030 as Usage and Demands Soars

Drone-Mounted Lidar Systems for Bathymetric Surveys Market Expected to Reach $890 Million By 2032

EHang to Report First Quarter 2025 Unaudited Financial Results on Monday, May 26, 2025

Drones Used for Power Line Inspection Industry Exploding, Expected to Reach $323 Billion By 2032

Targeting the Skies: 4 Drone Stocks With Breakout Potential

Earnings

EHang Reports First Quarter 2025 Unaudited Financial Results

ACHR

AVAV

BMV:ZENA

DPRO

KTOS

ONDS

PLTR

PRZO

RCAT

SPAI

UAVS

ZENA

Archer Aviation Inc. Class A Common Stock

Archer Aviation

AerSale

Astronics

Byrna Technologies

Cadre Hldgs

Ducommun

Eve Holding

Vertical Aerospace

Hexcel

Innovative Solutions and Support, Inc. - Common Stock

Innovative Solns

Kratos Defense & Security Solutions, Inc. - Common Stock

Kratos Defense & Security

Intuitive Machines, Inc. - Class A Common Stock

Intuitive Machines

Moog Inc. Class A Common Stock

Mercury Sys

National Presto Industries, Inc. Common Stock

National Presto Indus

Optex Systems Holdings, Inc. - Common Stock

Optex Systems Hldgs

Park Aerospace

Redwire

Satellogic

Virgin Galactic Holdings, Inc. Common Stock

Virgin Galactic Hldgs

Spirit Aerosystems Holdings, Inc. Common Stock

Comments

EHang Holdings

空売り

EHang Holdings (NASDAQ:EH) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル